Drug Profile


Alternative Names: ME 3167; ZK 62711

Latest Information Update: 07 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer Schering Pharma; Meiji Seika Kaisha
  • Class Antidepressants
  • Mechanism of Action Apoptosis stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Glioma; HIV-1 infections; Major depressive disorder; Rheumatoid arthritis

Most Recent Events

  • 29 Sep 1999 Preclinical development for Rheumatoid arthritis in Germany (PO)
  • 29 Sep 1999 Preclinical development for Rheumatoid arthritis in Japan (PO)
  • 29 Sep 1999 Two preclinical studies have been added to the Rheumatic Disease pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top